Extended effectiveness of PDLI's antibodies

Protein Design Labs Inc. (PDLI) has presented animal data showing that four of its human or humanized antibodies persist for several weeks, giving clues as to which products may be effective with infrequent dosing.

Murine monoclonals generally require once-a-day dosing, the company noted, whereas PDLI's results in Rhesus monkeys suggest that once every two weeks might suffice for certain human or humanized versions. Paul Nadler, vice president for medical and regulatory affairs, told BioCentury it now may make it possible to predict which products will work with infrequent dosing, ...